[{"recommendationid":7967468,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"atorvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://www.clinpgx.org/guideline/PA166264281","implications":{"SLCO1B1": "Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk"},"drugrecommendation":"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).","classification":"Moderate","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7968477,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"lovastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://www.clinpgx.org/guideline/PA166264281","implications":{"SLCO1B1": "Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk"},"drugrecommendation":"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.","classification":"Moderate","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7968803,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"pitavastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://www.clinpgx.org/guideline/PA166264281","implications":{"SLCO1B1": "Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk"},"drugrecommendation":"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).","classification":"Moderate","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7968809,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"pravastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://www.clinpgx.org/guideline/PA166264281","implications":{"SLCO1B1": "Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg."},"drugrecommendation":"Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.","classification":"Moderate","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}, 
 {"recommendationid":7968909,"lookupkey":{"SLCO1B1": "Decreased Function"},"drugname":"simvastatin","guidelinename":"SLCO1B1, ABCG2, CYP2C9, and Statins","guidelineurl":"https://www.clinpgx.org/guideline/PA166264281","implications":{"SLCO1B1": "Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy"},"drugrecommendation":"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.","classification":"Strong","phenotypes":{"SLCO1B1": "Decreased Function"},"activityscore":{},"population":"general","comments":"The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy."}]